Home > News Item Detail
Headache in the News ArchiveReuters -- MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM)
2009 Oct 29 MAP Pharmaceuticals,
Inc. (Nasdaq: MAPP) today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 http://www.reuters.com/article/pressRelease/idUS122343+29-Oct-2009+PRN20091029 Categories: Research |
Find a headache specialist near you:
From NHF HeadLines
Take Control of Your Headaches - Issue 175
NHF Features